全球肿瘤生物标记市场规模、份额、趋势和成长分析报告（2026-2034）

肿瘤生物标记市场预计将从 2025 年的 441.7 亿美元成长到 2034 年的 1,345 亿美元，2026 年至 2034 年的复合年增长率为 13.17%。

随着癌症诊断和治疗越来越依赖精准医疗，全球肿瘤生物标记市场正在迅速扩张。肿瘤生物标记有助于癌症的早期发现、预测治疗效果以及监测疾病进展。全球癌症发生率的上升以及对更精准诊断工具日益增长的需求，正在推动基于生物标记的检测方法在临床实践和研究中的应用。

分子诊断、基因测序和蛋白质体学技术的进步是推动市场成长的关键因素。生物标记广泛应用于标靶治疗和临床试验，以识别合适的患者群体并改善治疗效果。製药公司也在生物标记研究领域投入大量资金，以支持创新癌症治疗方法和个人化治疗方案的开发。

展望未来，在持续的研究和技术创新推动下，肿瘤生物标记市场预计将保持强劲成长。液态生物检体、伴随诊断和人工智慧数据分析的日益普及将进一步加速生物标记的发现和应用。随着医疗系统越来越重视癌症早期检测和个人化治疗策略，全球对肿瘤生物标记的需求将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球肿瘤生物标记市场：按类型划分

• 市场分析、洞察与预测
• 乳癌
• 摄护腺癌
• 结肠癌
• 子宫颈癌
• 肝癌
• 肺癌
• 其他的

第五章：全球肿瘤生物标记市场：依生物分子分类

• 市场分析、洞察与预测
• 基因生物标记
• 表观遗传生物标记
• 代谢生物标记
• 蛋白质体学生物标誌物
• 其他的

第六章 全球肿瘤生物标记市场：依应用划分

• 市场分析、洞察与预测
• 药物发现与开发
• 诊断
• 个人化医疗
• 其他的

第七章 全球肿瘤生物标记市场：依技术划分

• 市场分析、洞察与预测
• 成像技术
• 体学

第八章 全球肿瘤生物标记市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott
  • Qiagen
  • Thermo Fisher Scientific Inc
  • Affymetrix Inc
  • Illumina Inc
  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc
  • Hologic Inc
  • Sino Biological Inc

The Oncology Biomarker Market size is expected to reach USD 134.50 Billion in 2034 from USD 44.17 Billion (2025) growing at a CAGR of 13.17% during 2026-2034.

The global oncology biomarker market is expanding rapidly as cancer diagnosis and treatment increasingly rely on precision medicine. Oncology biomarkers help detect cancer at an early stage, predict treatment responses, and monitor disease progression. Rising cancer incidence worldwide and the need for more accurate diagnostic tools are driving the adoption of biomarker-based testing in clinical practice and research.

Advancements in molecular diagnostics, genomic sequencing, and proteomics technologies are major factors accelerating market growth. Biomarkers are widely used in targeted therapies and clinical trials to identify suitable patient populations and improve treatment outcomes. Pharmaceutical companies are also investing heavily in biomarker research to support the development of innovative cancer therapies and personalized treatment approaches.

Looking ahead, the oncology biomarker market is expected to witness strong growth due to continuous research and technological innovation. The increasing use of liquid biopsy, companion diagnostics, and AI-driven data analysis will further enhance biomarker discovery and application. As healthcare systems emphasize early cancer detection and personalized treatment strategies, the demand for oncology biomarkers will continue to rise globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Others

By Application

• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Others

By Technology

• Imaging Technology
• OMICS

COMPANIES PROFILED

• Abbott, Qiagen, Thermo Fisher Scientific Inc, Affymetrix Inc, Illumina Inc, Agilent Technologies, F HoffmannLa Roche AG, Merck Co Inc, Hologic Inc, Sino Biological Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLOGY BIOMARKER MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLOGY BIOMARKER MARKET: BY BIOMOLECULE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Biomolecule
• 5.2. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Epigenetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metabolic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Proteomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLOGY BIOMARKER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery and Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLOGY BIOMARKER MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Imaging Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. OMICS Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLOGY BIOMARKER MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Biomolecule
  • 8.2.3 By Application
  • 8.2.4 By Technology
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Biomolecule
  • 8.3.3 By Application
  • 8.3.4 By Technology
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Biomolecule
  • 8.4.3 By Application
  • 8.4.4 By Technology
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Biomolecule
  • 8.5.3 By Application
  • 8.5.4 By Technology
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Biomolecule
  • 8.6.3 By Application
  • 8.6.4 By Technology
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ONCOLOGY BIOMARKER INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott
  • 10.2.2 Qiagen
  • 10.2.3 Thermo Fisher Scientific Inc
  • 10.2.4 Affymetrix Inc
  • 10.2.5 Illumina Inc
  • 10.2.6 Agilent Technologies
  • 10.2.7 F. Hoffmann-La Roche AG
  • 10.2.8 Merck & Co. Inc
  • 10.2.9 Hologic Inc
  • 10.2.10 Sino Biological Inc